A Global Phase 2 Study of ARX788 in HER2-positiveMetastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1 and/or T-DXd and/or Tucatinib-containing Regimens

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.